デジタル治療薬（DTx）市場：アプリケーション別（糖尿病予備軍、栄養、介護、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリ）、販売チャネルB2C（患者、介護者）、B2B（プロバイダ、支払者、雇用者、製薬）-2027年までの世界市場予測

Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027

デジタル治療薬の世界市場は、2022年の45億米ドルから2027年には177億米ドルに達すると予測され、予測期間中のCAGRは31.6%となります。デジタル治療薬の採用は、慢性疾患患者の増加やデジタル治療薬への投資の増... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年10月24日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	224	223	英語

サマリー

デジタル治療薬の世界市場は、2022年の45億米ドルから2027年には177億米ドルに達すると予測され、予測期間中のCAGRは31.6%となります。デジタル治療薬の採用は、慢性疾患患者の増加やデジタル治療薬への投資の増加などの要因から、速いペースで拡大しています。しかし、発展途上国におけるデジタル・セラピューティクス・プログラムに対する認識やアクセスの不足、従来の医療提供者の抵抗、不均等な支払いモデルなどが、この市場の成長を阻む要因となっています。
2021年のデジタル治療薬市場は、治療/ケア関連アプリケーション分野が最大シェアを占める
デジタル治療薬市場は、用途別に予防分野と治療・介護関連分野に分けられます。このセグメントの大きなシェアは、これらの症状に対する費用対効果や拡張性の高い治療プラットフォームの開発を促進するため、デジタル治療薬への投資が増加していることに起因しています。

糖尿病分野は予測期間中に最も高い成長率を示すと予想される
デジタル治療薬市場は、治療・ケア関連アプリケーションの種類に基づいて、さらに糖尿病、CNS障害、慢性呼吸器疾患、筋骨格系障害、心血管疾患、禁煙、服薬遵守、胃腸障害、物質使用障害・依存症管理、リハビリ・患者ケア、その他の治療・ケア関連アプリケーションに分類されます。2021年、糖尿病は治療/ケア関連アプリケーションのデジタル治療薬市場で最大のシェアを占めました。糖尿病の有病率の増加、糖尿病に関連する高い医療費、費用対効果の高いソリューションの助けを借りて負担を減らすための政府の取り組みの高まりが、このセグメントの市場成長を促進すると予測されます。
B2B分野は予測期間中に最も高いCAGRで成長すると予想される
デジタル治療薬市場は、販売チャネルによってB2C（Business to Customer）とB2B（Business to Business）に分けられます。これは、製薬会社がデジタル治療薬を自社の医薬品に統合する傾向が強まっていることに起因しています。

北米が最大かつ最速で成長する地域市場へ

米国とカナダを含む北米は、2021年のデジタル・セラピューティクスで最大の市場シェアを占めています。デジタル治療薬の償還構造の改善や、技術的進歩を支援する政府の取り組みなどの要因が、この地域の市場成長を後押ししています。

本レポートのために実施した一次インタビューは、以下のように分類されます。
- 企業タイプ別ティア1（50％）、ティア2（30％）、ティア3（20％）。
- 役職別Cレベル(75%)、Dレベル(15%)、その他(10%)
- 地域別北米 (70%)、欧州 (20%)、APAC (7%)、RoW (3%)

本市場の主なプレイヤーは、Noom, Inc.（米国）、Teladoc Health, Inc.（米国）、Omada Health, Inc.（米国）、WellDoc, Inc.（米国）、Pear Therapeutics, Inc.（米国）、CogniFlex, Inc.(米国）、CogniFit Inc（米国）、Ginger（米国）、Propeller Health（米国）、2Morrow, Inc（米国）、Canary Health（米国）、Click Therapeutics, Inc（米国）、Akili, Inc.（米国）、Cognoa, Inc（米国）、Wellthy Therapeutics Pvt.Ltd.(インド）、Twill Inc.（米国）、Better Therapeutics, Inc（米国）、Mindstrong（米国）、Kaia Health（ドイツ）、BehaVR Inc（米国）、Ayogo（カナダ）、Mindable Health GmbH（ドイツ）、Virta Health Corp（米国）、Hinge Health, Inc.（米国）、Orexo AB（スウェーデン）およびFreespira（米国）です。
調査対象範囲
本レポートは、デジタル治療薬市場の調査を行っています。販売チャネル、アプリケーション、地域などの異なるセグメントにおける市場規模や今後の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイル、最近の開発、主要な市場戦略とともに、詳細な競合分析も行っています。

レポート購入の主なメリット
本レポートは、デジタル治療薬市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することにより、市場リーダー/新規参入者を支援します。また、本レポートは、利害関係者が競争環境を理解し、自社のビジネスを位置づけるための洞察を得て、適切な市場参入戦略を立てるのに役立ちます。また、利害関係者が市場の脈拍を測定し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することが可能になります。

ページTOPに戻る

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 31
1.4 YEARS CONSIDERED 31
1.5 CURRENCY CONSIDERED 32
1.6 STAKEHOLDERS 32
1.7 LIMITATIONS 32
1.8 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
FIGURE 2 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
FIGURE 3 KEY INDUSTRY INSIGHTS 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION 39
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
2.2.1.1 Approach one: Revenue mapping-based estimation 40
FIGURE 6 DIGITAL THERAPEUTICS: REVENUE MAPPING-BASED ESTIMATION 41
2.2.1.2 Approach two: Buyer adoption-based estimation 41
FIGURE 7 DIGITAL THERAPEUTICS ESTIMATION: BUYER ADOPTION-BASED ESTIMATION 41
2.2.2 TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION 42
FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION 42
2.2.3 GROWTH FORECAST 42
TABLE 1 FACTOR ANALYSIS 43
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 44
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 45
FIGURE 11 DATA TRIANGULATION METHODOLOGY 46
2.4 ASSUMPTIONS 46
2.5 RISK ASSESSMENT 47
3 EXECUTIVE SUMMARY 48
FIGURE 12 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022 VS. 2027 (USD MILLION) 48
FIGURE 13 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, 2022 VS. 2027 (USD MILLION) 49
FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, 2022–2027 49
FIGURE 15 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (2022–2027) 50
FIGURE 16 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2022 VS. 2027 (USD MILLION) 51
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF DIGITAL THERAPEUTICS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW 53
FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS TO DRIVE ADOPTION OF DIGITAL THERAPEUTICS 53
4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022–2027 54
FIGURE 19 B2B SALES DOMINATE DIGITAL THERAPEUTICS MARKET 54
4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 NORTH AMERICA TO GROW AT HIGHEST RATE 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing incidence of preventable chronic diseases 57
5.2.1.2 Rising focus on preventive healthcare 57
5.2.1.3 Need to control healthcare costs 58
5.2.1.4 Significant increase in venture capital investments 58
5.2.1.5 Benefits of digital therapeutics 59
5.2.1.5.1 Ability to induce behavioral change 59
5.2.1.5.2 Improved drug adherence 60
5.2.1.5.3 Patient convenience and user-friendliness 60
5.2.2 RESTRAINTS 60
5.2.2.1 Patient data privacy concerns 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Emerging markets 61
5.2.3.2 Large undiagnosed and untreated population 61
5.2.3.3 Unexplored therapeutic applications 62
5.2.4 CHALLENGES 62
5.2.4.1 Unstable payment models 62
5.2.4.2 Reluctance among patients to adopt digital therapeutics 62
5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries 63
5.2.4.4 Resistance from traditional healthcare providers 63
5.3 SUPPLY/VALUE CHAIN ANALYSIS 63
FIGURE 22 VALUE CHAIN ANALYSIS 64
5.4 ECOSYSTEM ANALYSIS 65
FIGURE 23 ECOSYSTEM ANALYSIS 65
5.5 PIPELINE PRODUCTS 66
5.6 CASE STUDIES 67
5.7 PORTER’S FIVE FORCES ANALYSIS 68
5.7.1 THREAT OF NEW ENTRANTS 68
5.7.2 BARGAINING POWER OF SUPPLIERS 68
5.7.3 BARGAINING POWER OF BUYERS 69
5.7.4 THREAT OF SUBSTITUTES 69
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.8 REGULATORY LANDSCAPE 69
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 2 DIGITAL THERAPEUTICS REGULATORY FRAMEWORK 70
TABLE 3 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES 71
5.9 TECHNOLOGY TRENDS 72
TABLE 4 TECHNOLOGY ENABLERS, BENEFITS, AND EXAMPLES 72
5.10 INDUSTRY TRENDS 72
5.10.1 VIRTUAL REALITY 72
5.10.2 INCREASING DEMAND FOR DIGITAL DELIVERY OF BEHAVIORAL THERAPY 73
5.10.3 GROWING COLLABORATIONS BETWEEN STAKEHOLDERS 73
TABLE 5 DIGITAL THERAPEUTICS: RECENT COLLABORATIONS 73
5.11 PRICING ANALYSIS & REIMBURSEMENT SCENARIO 74
5.11.1 AVERAGE SELLING PRICE 74
TABLE 6 DIGITAL THERAPEUTICS PRODUCTS: REIMBURSEMENT & PRICE BY COUNTRY 74
5.11.2 REIMBURSEMENT SCENARIO 74
TABLE 7 DIGITAL THERAPEUTICS: GLOBAL COVERAGE DETERMINATION STANDARDS 75
5.12 PATENT ANALYSIS 76
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023 76
TABLE 8 DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 76
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 77
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 77
FIGURE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL 77
TABLE 9 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL 78
5.14.2 BUYING CRITERIA 78
FIGURE 25 KEY BUYING CRITERIA FOR SALES CHANNEL 78
TABLE 10 KEY BUYING CRITERIA FOR SALES CHANNEL 79
6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION 80
6.1 INTRODUCTION 81
TABLE 11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81
6.2 TREATMENT/CARE-RELATED APPLICATIONS 81
TABLE 12 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 13 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 82
6.2.1 DIABETES 83
6.2.1.1 Rising prevalence of diabetes to drive market growth 83
TABLE 14 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2020–2027 (USD MILLION) 83
6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS 83
TABLE 15 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 16 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2020–2027 (USD MILLION) 84
6.2.2.1 Mental health disorders 84
6.2.2.1.1 Benefits of digital therapeutics in managing mental health disorders to drive R&D 84
TABLE 17 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2020–2027 (USD MILLION) 85
6.2.2.2 Other CNS disorders 85
TABLE 18 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2020–2027 (USD MILLION) 85
6.2.3 SMOKING CESSATION 86
6.2.3.1 Focus on providing validated, effective mobile applications to help quit smoking to aid market growth 86
TABLE 19 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2020–2027 (USD MILLION) 86
6.2.4 CHRONIC RESPIRATORY DISEASES 86
6.2.4.1 Growing prevalence of COPD and asthma to drive market growth 86
TABLE 20 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2020–2027 (USD MILLION) 87
6.2.5 MUSCULOSKELETAL DISORDERS 87
6.2.5.1 Dearth of physiotherapists to support market growth 87
TABLE 21 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 87
6.2.6 CARDIOVASCULAR DISEASE 88
6.2.6.1 High burden of CVD to drive demand for digital therapeutics solutions 88
TABLE 22 DIGITAL THERAPEUTICS MARKET FOR CVD, BY REGION, 2020–2027 (USD MILLION) 88
6.2.7 MEDICATION ADHERENCE 88
6.2.7.1 Growing number of medication non-adherence cases to propel market growth 88
TABLE 23 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2020–2027 (USD MILLION) 89
6.2.8 GASTROINTESTINAL DISORDERS 89
6.2.8.1 High prevalence of gastrointestinal disorders to ensure strong interest in developing targeted solutions 89
TABLE 24 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 89
6.2.9 REHABILITATION & PATIENT CARE 90
6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care 90
TABLE 25 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2020–2027 (USD MILLION) 90
6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 90
6.2.10.1 Potential to improve efficiency of behavioral interventions to drive market growth 90
TABLE 26 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2020–2027 (USD MILLION) 91
6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS 91
TABLE 27 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 91
6.3 PREVENTIVE APPLICATIONS 92
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 93
6.3.1 PREDIABETES 93
6.3.1.1 Influx of startups to provide effective prevention against prediabetes to support market 93
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2020–2027 (USD MILLION) 93
6.3.2 OBESITY 94
6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth 94
TABLE 31 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION) 94
6.3.3 NUTRITION 94
6.3.3.1 Importance of nutrition in preventing a wide range of ailments to drive demand for digital therapeutic solutions 94
TABLE 32 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2020–2027 (USD MILLION) 95
6.3.4 LIFESTYLE MANAGEMENT 95
6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes to contribute to rising demand 95
TABLE 33 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2020–2027 (USD MILLION) 96
6.3.5 OTHER PREVENTIVE APPLICATIONS 96
TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 97
7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL 98
7.1 INTRODUCTION 99
TABLE 35 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 99
7.2 B2B 99
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 99
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2020–2027 (USD MILLION) 100
7.2.1 PAYERS 100
7.2.1.1 Payers to hold largest share of B2B market 100
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2020–2027 (USD MILLION) 101
7.2.2 EMPLOYERS 101
7.2.2.1 Rising importance of employee health management to drive adoption of digital therapeutics among employers 101
TABLE 39 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2020–2027 (USD MILLION) 102
7.2.3 PHARMACEUTICAL COMPANIES 102
7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth 102
TABLE 40 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 103
7.2.4 PROVIDERS 103
7.2.4.1 Potential for better patient management and cost-reduction to drive demand for digital therapeutics among providers 103
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2020–2027 (USD MILLION) 104
7.2.5 OTHER BUYERS 104
TABLE 42 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2020–2027 (USD MILLION) 104
7.3 B2C 104
TABLE 43 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 105
TABLE 44 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2020–2027 (USD MILLION) 105
7.3.1 CAREGIVERS 105
7.3.1.1 Ease of managing health conditions to drive demand for solutions among caregivers 105
TABLE 45 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2020–2027 (USD MILLION) 106
7.3.2 PATIENTS 106
7.3.2.1 Awareness of preventive health among patients to support segment growth 106
TABLE 46 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2020–2027 (USD MILLION) 106
8 DIGITAL THERAPEUTICS MARKET, BY REGION 107
8.1 INTRODUCTION 108
TABLE 47 DIGITAL THERAPEUTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 108
8.2 NORTH AMERICA 108
FIGURE 26 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT 109
TABLE 48 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 49 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 50 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 51 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 52 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 53 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 112
TABLE 54 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 112
TABLE 55 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 113
8.2.1 US 113
8.2.1.1 Strong start-up base to ensure high product access for end users 113
TABLE 56 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 57 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 58 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 59 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 60 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 116
TABLE 61 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 116
TABLE 62 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 117
8.2.2 CANADA 117
8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada 117
TABLE 63 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 118
TABLE 64 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 65 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 66 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 67 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 119
TABLE 68 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 120
TABLE 69 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 120
8.3 EUROPE 120
FIGURE 27 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT 121
TABLE 70 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 71 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 72 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 73 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 74 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 75 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 124
TABLE 76 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 124
TABLE 77 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 125
8.3.1 GERMANY 125
8.3.1.1 Germany forms largest market for digital therapeutics in Europe due to supportive government initiatives 125
TABLE 78 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 79 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 80 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 81 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 82 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 127
TABLE 83 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 128
TABLE 84 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 128
8.3.2 UK 128
8.3.2.1 Well-established healthcare system and government support to propel market 128
TABLE 85 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 86 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 87 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 88 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 89 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 131
TABLE 90 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 131
TABLE 91 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 132
8.3.3 FRANCE 132
8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market 132
TABLE 92 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133
TABLE 93 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 133
TABLE 94 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 95 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 96 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 134
TABLE 97 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 135
TABLE 98 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 135
8.3.4 SPAIN 135
8.3.4.1 Initiatives by emerging digital therapeutics startups to drive market 135
TABLE 99 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136
TABLE 100 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 101 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 102 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 103 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 137
TABLE 104 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 138
TABLE 105 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 138
8.3.5 ITALY 138
8.3.5.1 Need for alternative and effective treatment to drive market 138
TABLE 106 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 107 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 108 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 109 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 110 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 140
TABLE 111 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 141
TABLE 112 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 141
8.3.6 REST OF EUROPE 141
TABLE 113 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 114 ROE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 115 ROE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 116 ROE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 117 ROE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 143
TABLE 118 ROE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 144
TABLE 119 ROE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 144
8.4 ASIA PACIFIC 145
TABLE 120 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 121 APAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 122 APAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 123 APAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 124 APAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 125 APAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 147
TABLE 126 APAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 147
TABLE 127 APAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 148
8.4.1 JAPAN 148
8.4.1.1 Rising diabetes incidence and collaborations to drive market growth 148
TABLE 128 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 148
TABLE 129 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 130 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 131 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 132 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 150
TABLE 133 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 150
TABLE 134 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 151
8.4.2 CHINA 151
8.4.2.1 Growing geriatric population and incidence of chronic conditions to drive demand 151
TABLE 135 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 151
TABLE 136 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 137 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 138 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 139 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 153
TABLE 140 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 153
TABLE 141 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 154
8.4.3 INDIA 154
8.4.3.1 Rising chronic disease incidence and need for better disease management to drive market 154
TABLE 142 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 155
TABLE 143 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 144 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 145 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 146 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 156
TABLE 147 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 157
TABLE 148 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 157
8.4.4 REST OF ASIA PACIFIC 157
TABLE 149 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 150 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 151 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 152 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 153 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 159
TABLE 154 ROAPAC DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 160
TABLE 155 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 160
8.5 REST OF THE WORLD 160
TABLE 156 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 161
TABLE 157 ROW: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 158 ROW: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 159 ROW: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 160 ROW: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 162
TABLE 161 ROW: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 163
TABLE 162 ROW: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 163
9 COMPETITIVE LANDSCAPE 164
9.1 OVERVIEW 164
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 164
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL THERAPEUTICS 165
9.3 MARKET SHARE ANALYSIS 166
TABLE 163 DIGITAL THERAPEUTICS MARKET: DEGREE OF COMPETITION 166
FIGURE 29 MARKET SHARE ANALYSIS: DIGITAL THERAPEUTICS MARKET 167
9.4 MARKET RANKING ANALYSIS, 2022 167
FIGURE 30 DIGITAL THERAPEUTICS MARKET RANKING ANALYSIS, 2022 167
9.5 COMPETITIVE BENCHMARKING 168
TABLE 164 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 168
TABLE 165 DIGITAL THERAPEUTICS MARKET: SALES CHANNEL FOOTPRINT OF KEY PLAYERS 169
TABLE 166 DIGITAL THERAPEUTICS MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 169
9.5.1 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY 169
TABLE 167 DIGITAL THERAPEUTICS MARKET: CRITERIA CONSIDERED FOR EVALUATION 169
9.5.1.1 Stars 170
9.5.1.2 Emerging leaders 170
9.5.1.3 Pervasive players 170
9.5.1.4 Participants 170
FIGURE 31 DIGITAL THERAPEUTICS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2022 171
9.5.2 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2022) 172
9.5.2.1 Progressive companies 172
9.5.2.2 Starting blocks 172
9.5.2.3 Responsive companies 172
9.5.2.4 Dynamic companies 172
FIGURE 32 DIGITAL THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022 173
9.6 COMPETITIVE SCENARIO 174
TABLE 168 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2019– AUGUST 2022 174
9.6.1 DEALS 175
TABLE 169 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2019 - AUGUST 2022 175
9.6.2 OTHER DEVELOPMENTS 176
TABLE 170 DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2019 - AUGUST 2022 176
10 COMPANY PROFILES 177
10.1 KEY PLAYERS 177
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOOM 177
TABLE 171 NOOM: BUSINESS OVERVIEW 177
10.1.2 TELADOC HEALTH 180
TABLE 172 TELADOC HEALTH: BUSINESS OVERVIEW 180
FIGURE 33 TELADOC HEALTH: COMPANY SNAPSHOT (2021) 180
10.1.3 OMADA HEALTH 183
TABLE 173 OMADA HEALTH: BUSINESS OVERVIEW 183
10.1.4 WELLDOC 186
TABLE 174 WELLDOC: BUSINESS OVERVIEW 186
10.1.5 PEAR THERAPEUTICS 189
TABLE 175 PEAR THERAPEUTICS: BUSINESS OVERVIEW 189
10.1.6 COGNIFIT 194
TABLE 176 COGNIFIT: BUSINESS OVERVIEW 194
10.1.7 GINGER 196
TABLE 177 GINGER: BUSINESS OVERVIEW 196
10.1.8 PROPELLER HEALTH 198
TABLE 178 PROPELLER HEALTH: BUSINESS OVERVIEW 198
10.1.9 2MORROW 199
TABLE 179 2MORROW: BUSINESS OVERVIEW 199
10.1.10 CANARY HEALTH 201
TABLE 180 CANARY HEALTH: BUSINESS OVERVIEW 201
10.1.11 CLICK THERAPEUTICS 203
TABLE 181 CLICK THERAPEUTICS: BUSINESS OVERVIEW 203
10.1.12 AKILI 205
TABLE 182 AKILI: BUSINESS OVERVIEW 205
10.1.13 WELLTHY THERAPEUTICS 207
TABLE 183 WELLTHY THERAPEUTICS: BUSINESS OVERVIEW 207
10.1.14 COGNOA 209
TABLE 184 COGNOA: BUSINESS OVERVIEW 209
10.1.15 TWILL 211
TABLE 185 TWILL: BUSINESS OVERVIEW 211
10.1.16 KAIA HEALTH 213
TABLE 186 KAIA HEALTH: BUSINESS OVERVIEW 213
10.1.17 BETTER THERAPEUTICS 215
TABLE 187 BETTER THERAPEUTICS: BUSINESS OVERVIEW 215
10.1.18 MINDSTRONG HEALTH 217
TABLE 188 MINDSTRONG HEALTH: BUSINESS OVERVIEW 217
10.1.19 BEHAVR 218
TABLE 189 BEHAVR: BUSINESS OVERVIEW 218
10.1.20 AYOGO 220
TABLE 190 AYOGO: BUSINESS OVERVIEW 220
10.2 OTHER PLAYERS 221
10.2.1 MINDABLE HEALTH 221
10.2.2 VIRTA HEALTH CORP 221
10.2.3 HINGE HEALTH 222
10.2.4 OREXO AB 222
10.2.5 FREESPIRA 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 224
11.1 DISCUSSION GUIDE 224
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 228
11.3 CUSTOMIZATION OPTIONS 230
11.4 RELATED REPORTS 230
11.5 AUTHOR DETAILS 231

ページTOPに戻る

Table of Contents

Summary

The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period. The adoption of digital therapeutics is growing at a fast pace owing to factors such as rise in number of patients with chronic diseases and growing investments in digital therapeutics. However, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and uneven payment models are challenging the growth of this market.
Treatment/care-related applications segment hold the largest share of the digital therapeutics market in 2021
On the basis of application, the digital therapeutics market is divided into preventive and treatment/care-related applications. The large share of this segment is attributed to the rising investments in digital therapeutics to promote the development of cost-effective and scalable treatment platforms for these conditions.

Diabetes segment is expected to grow at the highest rate during the forecast period
On the basis of type of treatment/care-related application, the digital therapeutics market is further dividedinto diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications. In 2021, diabetes commanded the largest share of the digital therapeutics market for treatment/care-related applications. The increasing prevalence of diabetes, high healthcare costs associated with diabetes, and rising government initiatives to decrease the burden with the help of cost-effective solutions are expected to drive the market growth in this segment.
B2B segment is expected to grow with the highest CAGR during the forecast period
On the basis of sales channel, the digital therapeutics market is divided into business-to-customer (B2C) and business-to-business (B2B). This is attributed to growing inclination of pharma companies to integrate digital therapeutics with their drug products.

North America to be the largest and the fastest-growing regional market

North America, which includes the US and Canada, holds the largest market share for digital therapeutics in 2021. Factors such as the improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
• By Designation: C-level (75%), D-level (15%), and Others (10%)
• By Region: North America (70%), Europe (20%), APAC (7%), and the RoW (3%)

The prominent players in this market are Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US).
Research Coverage:
This report provides a study of the digital therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as sales channel, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall digital therapeutics market and its subsegments. This report will also help stakeholders understand the competitive landscape, gain insights to position their business, and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, restraints, opportunities and challenges.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（通信回線）の最新刊レポート

MarketsandMarkets社の通信回線分野での最新刊レポート

本レポートと同じKEY WORD（therapeutics）の最新刊レポート

ピーナッツアレルギー治療薬の世界市場規模、メーカー、サプライチェーン、販売チャネル、顧客、2022-2028年

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（通信回線）の最新刊レポート

MarketsandMarkets社の通信回線分野での最新刊レポート

本レポートと同じKEY WORD（therapeutics）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?